scholarly journals Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation

2017 ◽  
Vol 52 (6) ◽  
pp. 870-877 ◽  
Author(s):  
L Chee ◽  
M Tacey ◽  
B Lim ◽  
A Lim ◽  
J Szer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Disease Risk ◽  
Risk Index ◽  
Survival Outcome

scholarly journals Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3664-3671 ◽  
Author(s):  
Philippe Armand ◽  
Haesook T. Kim ◽  
Brent R. Logan ◽  
Zhiwei Wang ◽  
Edwin P. Alyea ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Disease Risk ◽  
Risk Index ◽  
Allogeneic Transplantation ◽  
Key Points ◽  
Conditioning Intensity

Key Points The DRI successfully stratified patients in a very large allogeneic transplantation registry cohort. The DRI was refined by using this cohort to build a more inclusive and conditioning intensity–independent index.

Validating the Allogeneic Stem Cell Transplantation Disease Risk Index

2015 ◽  
Vol 99 (1) ◽  
pp. 128-132 ◽  
Author(s):  
Andrew B.M. Lim ◽  
Andrew W. Roberts ◽  
Kate Mason ◽  
Ashish Bajel ◽  
Jeff Szer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Disease Risk ◽  
Risk Index

scholarly journals A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

2021 ◽  
Vol 11 (11) ◽  
Author(s):  
Kalyan Nadiminti ◽  
Kimberly Langer ◽  
Ehsan Shabbir ◽  
Mehrdad Hefazi ◽  
Lindsay Dozeman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Cox Regression ◽  
Disease Risk ◽  
Risk Index ◽  
Disease Free Survival ◽  
Donor Age ◽  
Hematopoietic Stem ◽  
Cmv Status

AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for many hematologic conditions and is associated with considerable morbidity and mortality. Therefore, prognostic tools are essential to navigate the complex patient, disease, donor, and transplant characteristics that differentially influence outcomes. We developed a novel, comprehensive composite prognostic tool. Using a lasso-penalized Cox regression model (n = 273), performance status, HCT-CI, refined disease-risk index (rDRI), donor and recipient CMV status, and donor age were identified as predictors of disease-free survival (DFS). The results for overall survival (OS) were similar except for recipient CMV status not being included in the model. Models were validated in an external dataset (n = 378) and resulted in a c-statistic of 0.61 and 0.62 for DFS and OS, respectively. Importantly, this tool incorporates donor age as a variable, which has an important role in HSCT outcomes. This needs to be further studied in prospective models. An easy-to-use and a web-based nomogram can be accessed here: https://allohsctsurvivalcalc.iowa.uiowa.edu/.

Disease Risk Index Is the Major Predictor of Outcome Following Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) and Post-Transplant Cyclophosphamide (PT/Cy)

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2010-2010 ◽  
Author(s):  
Scott R. Solomon ◽  
Connie Sizemore ◽  
Xu Zhang ◽  
Melhem Solh ◽  
Lawrence E. Morris ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Disease Risk ◽  
Risk Index ◽  
Hematopoietic Stem ◽  
Major Predictor ◽  
One Year ◽  
Very High

Abstract Disease Risk Index is the Major Predictor of Outcome Following Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) and Post-Transplant Cyclophosphamide (PT/Cy) Although non-myeloablative (NMA) haplo-HSCT utilizing PT/Cy results in low rates of GVHD, infection, and non-relapse mortality (NRM), relapse remains the predominant cause of treatment failure, occurring in up to 50% of patients. To reduce the risk of relapse often associated with the use of NMA preparative regimens, we have developed a myeloablative haplo-HSCT utilizing PT/Cy. Sixty-four patients have been transplanted following either Busulfan-based (n=20) or TBI-based (n=44) myeloablative conditioning, T-cell replete PBSC infusion, PT/Cy, and tacrolimus/mycophenolate mofetil. Median age was 43 (range 21-60). Patient characteristics included a high/very high disease risk by the Dana-Farber/CIBMTR disease risk index (DRI) in 32 patients (50%), KPS<90 in 69%, and comorbidity index (CMI) of ≥2 in 58% of patients. The most common indications for transplant were AML, ALL, and advanced-phase CML in 55%, 20% and 12% of patients respectively. Median follow-up for surviving patients was 24 months. All patients have engrafted with no late graft failure. Grade II-IV, III-IV acute GVHD and moderate-severe chronic GVHD occurred in 46%, 23%, and 30% respectively. One-year NRM was 10%. Predicted three-year overall survival (OS), disease-free survival (DFS), and relapse are 53%, 53%, and 26% respectively. In multivariate analysis, high/very high DRI was the most significant negative predictor of OS (HR 13.26, p<0.001), followed by CMI≥2 (HR 3.54, p=0.01) and age (HR 1.26, p=0.038, per each 5 year increase in age). DRI was also significantly associated with DFS (HR 10.84, p<0.001), NRM (HR 15.0, p=0.004), and relapse (HR 8.85, p=0.004). In the 32 patients with standard risk disease (low/intermediate DRI), outcomes were significantly improved with one-year NRM of 0% and predicted 3-year OS, DFS, and relapse of 79%, 74% and 9% respectively. Conditioning regimen (TBI vs. Busulfan) had no significant impact on outcome. This analysis confirms that DRI is a strong predictor of outcome following myeloablative haplo-HSCT and PT/Cy and adds to a growing body of literature suggesting that haplo-HSCT is a safe and effective transplant option for patients lacking a matched sibling donor. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document